High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 2018
Journal of Antimicrobial Chemotherapy2021Vol. 76(5), pp. 1221–1228
Citations Over TimeTop 10% of 2021 papers
Magnus Unemo, Josefine Ahlstrand, Leonor Sánchez-Busó, Michaela Day, David M. Aanensen, Daniel Golparian, Susanne Jacobsson, Michelle Cole, the European Collaborative Group, Raquel Abad Torreblanca, Lena Rós Ásmundsdóttir, Eszter Balla, Irith De Baetselier, Béatrice Berçot, Anna Carannante, Dominique Caugant, Maria José Borrego, Susanne Buder, Robert Cassar, Michelle Cole, Alje P. van Dam, Claudia Eder, Steen Hoffmann, Blaženka Hunjak, Samo Jeverica, Vesa Kirjavainen, Panayiota Maikanti-Charalambous, Vivì Miriagou, Beata Młynarczyk-Bonikowska, Gatis Pakarna, Lynsey Patterson, Peter Pavlik, Monique Perrin, Jill Shepherd, Paola Stefanelli, Magnus Unemo, Jelena Viktorova, Hana Zákoucká
Abstract
The in vitro susceptibility to zoliflodacin was high and the zoliflodacin target GyrB was conserved among EU/EEA gonococcal isolates in 2018. This study supports further clinical development of zoliflodacin. However, additional zoliflodacin data regarding particularly the treatment of pharyngeal gonorrhoea, pharmacokinetics/pharmacodynamics and resistance selection, including suppression, would be valuable.
Related Papers
- → Establishing Novel Molecular Algorithms to Predict Decreased Susceptibility to Ceftriaxone in Neisseria gonorrhoeae Strains(2020)25 cited
- Comparison of Azithromycin versus Cefixime for Treatment of Bacterial Diarrhea in Children.(2005)
- First Isolation of Ceftriaxone-Resistant Neisseria Gonorrhoeae in Nanchang(2002)
- → Study on early administration of azithromycin in the treatment of lower respiratory tract infection in children(2019)
- Ceftriaxone resistance in Neisseria gonorrhoeae: research advances.(2009)